Marshall Wace LLP Increases Holdings in Agilent Technologies, Inc. $A

Marshall Wace LLP lifted its holdings in Agilent Technologies, Inc. (NYSE:A) by 2.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,511,123 shares of the medical research company’s stock after acquiring an additional 42,476 shares during the period. Marshall Wace LLP owned 0.53% of Agilent Technologies worth $178,328,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Stone House Investment Management LLC bought a new stake in shares of Agilent Technologies in the 1st quarter valued at approximately $30,000. Ransom Advisory Ltd purchased a new stake in Agilent Technologies during the 1st quarter valued at $32,000. Central Pacific Bank Trust Division bought a new stake in Agilent Technologies in the second quarter worth $33,000. Zions Bancorporation National Association UT purchased a new position in Agilent Technologies during the first quarter worth $38,000. Finally, Ameritas Advisory Services LLC purchased a new position in Agilent Technologies during the second quarter worth $64,000.

Insider Activity

In other Agilent Technologies news, VP Rodney Gonsalves sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total transaction of $464,970.00. Following the transaction, the vice president owned 31,846 shares of the company’s stock, valued at approximately $4,935,811.54. This trade represents a 8.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Padraig Mcdonnell sold 12,490 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the completion of the sale, the chief executive officer directly owned 33,448 shares of the company’s stock, valued at $5,017,200. The trade was a 27.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 16,401 shares of company stock worth $2,468,962.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on A shares. Wells Fargo & Company raised their target price on shares of Agilent Technologies from $150.00 to $175.00 and gave the stock an “overweight” rating in a report on Tuesday, November 25th. TD Cowen raised their price objective on shares of Agilent Technologies from $150.00 to $162.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. boosted their target price on Agilent Technologies from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Tuesday, November 25th. Evercore ISI raised their price target on Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 7th. Finally, Morgan Stanley started coverage on Agilent Technologies in a report on Tuesday. They set an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $161.08.

Agilent Technologies Stock Performance

Agilent Technologies stock opened at $148.08 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96. The company has a market capitalization of $41.98 billion, a PE ratio of 32.40, a P/E/G ratio of 4.33 and a beta of 1.27. The company has a 50 day moving average price of $144.40 and a 200-day moving average price of $127.69. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $160.27.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.01. The company had revenue of $1.86 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Agilent Technologies had a return on equity of 25.20% and a net margin of 18.75%.Agilent Technologies’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. As a group, equities analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Investors of record on Tuesday, January 6th will be paid a $0.255 dividend. This represents a $1.02 dividend on an annualized basis and a yield of 0.7%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.25. The ex-dividend date of this dividend is Tuesday, January 6th. Agilent Technologies’s payout ratio is currently 21.66%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.